Silence Says It Is In Talks Over Potential Sale

Details about the "approach, which may or may not lead to an offer for the company," will be provided "in due course," Silence said. The news comes as an more and more drug makers are opting to acquire RNAi shops with technologies of interest rather than collaborating with them.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.